B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
ZBIO
Zenas BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA acceptance of the obexelimab BLA, strong INDIGO Phase 3 efficacy cited by the company, substantial cash resources and multiple late-2026 milestones create a credible path to further regulatory and pipeline de-risking. [#SEC-8K-2026-08-13]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.0.
What can break
CFO transition at the end of September adds execution and reporting-transition risk.
Momentum
88
Value
41
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $34.00 · Bull $52.00 · Bear $20.00Analysis 2026-08-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $47.00
Why
Momentum88 · Δ7d +1.2
Value41 · Δ7d -0.0
Sentiment79 · Δ7d +5.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.0.
Contradictions & invalidation
- • CFO transition at the end of September adds execution and reporting-transition risk.
- • Clinical-stage cash burn may require additional financing and dilution.
- • Zenas remains clinical-stage with limited reported revenue, meaningful dependence on obexelimab, binary SunStone and ZB021 outcomes, commercialization-execution risk and potential financing or dilution risk.
Catalyst clock
2026-08-13
Post-earnings update confirms regulatory progress and cash runway
Lead driver: Sentiment · See AI snapshot
Momentum
88
9% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
+5.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-5.2
Sentiment
79
62% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
-2.4
Why this grade
Composite grade A. Momentum 88.2 / Value 41.2 / Sentiment 79.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-21. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.99B
Beta
-
Shares Out
65.18M
P/E (TTM) · Derived
-3.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.99
Rev YoY
-100.0%
EPS YoY
+41.6%
Gross Margin
+96.9%
Op Margin
-
Net Debt
-$263.23M
Current Ratio
9.93
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data